A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
Melissa T Bu1,2, Long Yuan1,2, Alyssa N Klee1,2
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Abstract:
Blockade of the PD-L1/PD-1 pathway has proven to be a broadly effective cancer immunotherapy. FDA-approved therapeutic monoclonal antibodies (mAbs) targeting the pathway have high affinity, blocking capacity, and low antibody effector activity. A number of rat antimouse mAbs have been used to model cancer immunotherapy in mouse models. We set forth the amino acid sequences of mAbs specific for mouse PD-1 (29F.1A12) and PD-L1 (10F.9G2) and compare their avidities, blocking capacities, biological activities, and epitope recognition with other commonly used mAbs. Further manipulation of these sequences should facilitate better modeling of immunotherapy in mouse models and the generation of novel agents.
Insights
Researchers characterized mouse anti-PD-1 and anti-PD-L1 monoclonal antibodies (mAbs) for cancer immunotherapy research. Understanding these antibody sequences aids in developing improved mouse models and novel therapeutic agents.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- The programmed cell death protein ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) pathway is a key target in cancer immunotherapy.
- Therapeutic monoclonal antibodies (mAbs) targeting this pathway are FDA-approved and demonstrate high efficacy.
- Existing rat anti-mouse mAbs are utilized for preclinical cancer immunotherapy modeling.
Purpose of the Study:
- To provide the amino acid sequences for mouse anti-PD-1 (29F.1A12) and anti-PD-L1 (10F.9G2) monoclonal antibodies (mAbs).
- To compare the characteristics of these mAbs with other commonly used antibodies in cancer immunotherapy research.
- To facilitate improved mouse models for immunotherapy and the development of new therapeutic agents.
Main Methods:
- Sequencing of anti-mouse PD-1 mAb (29F.1A12) and anti-mouse PD-L1 mAb (10F.9G2).
- Comparative analysis of antibody avidity, blocking capacity, and biological activity.
- Epitope recognition studies for the characterized mAbs.
Main Results:
- Detailed amino acid sequences for mouse anti-PD-1 and anti-PD-L1 mAbs are presented.
- Comparative data on avidity, blocking, and biological activity against other mAbs are established.
- Insights into epitope recognition profiles are provided.
Conclusions:
- The characterized mAbs provide valuable tools for preclinical cancer immunotherapy research.
- Sequence information can guide the engineering of enhanced antibodies for improved mouse models.
- This work supports the development of next-generation immunotherapeutic agents.
